Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study

Overview of attention for article published in Thrombosis Journal, December 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Readers on

mendeley: 42 Mendeley

Summary Policy documents X

So far, Altmetric has seen 2 policy documents that reference this research output.

rivaroxaban

Cited by Canadian Agency for Drugs and Technologies in Health on 21 Sep 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.